COYA THERAPEUTICS INC宣布，其针对额颞叶痴呆症（FTD）的候选药物Coya 302，其研究性新药（IND）申请已获得美国食品药品监督管理局（FDA）的正式受理。这一关键进展标志着该药物向临床开发阶段迈出了重要一步。
COYA THERAPEUTICS INC宣布，其针对额颞叶痴呆症（FTD）的候选药物Coya 302，其研究性新药（IND）申请已获得美国食品药品监督管理局（FDA）的正式受理。这一关键进展标志着该药物向临床开发阶段迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.